Phase I–II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo

Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?

(2011) Harold J. Burstein   JOURNAL OF CLINICAL ONCOLOGY

Hsp90 Inhibitor-Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage

(2011) K. Ha et al.   MOLECULAR CANCER THERAPEUTICS

Suberoylanilide hydroxamic acid partly reverses resistance to paclitaxel in human ovarian cancer cell lines

(2010) Adriano Angelucci et al.   GYNECOLOGIC ONCOLOGY

A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors

(2010) Mark Andrew Dickson et al.   INVESTIGATIONAL NEW DRUGS

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study

(2010) Anne Hansen Ree et al.   LANCET ONCOLOGY

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

(2009) Taofeek K. Owonikoko et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

(2009) Evanthia Galanis et al.   JOURNAL OF CLINICAL ONCOLOGY

Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer

(2009) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of Acetylation and Extracellular Location of Heat Shock Protein 90  in Tumor Cell Invasion

(2008) Y. Yang et al.   CANCER RESEARCH

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH